Once-Weekly HIV Pill Matches Daily Treatment in Global Study
A once-weekly HIV pill combining islatravir and lenacapavir is as effective as a daily regimen, according to an international Phase 3 study published in August 2026. The finding could simplify treatment for millions of people living with HIV worldwide.
A once-weekly HIV pill works just as well as a daily treatment regimen, according to results from a large international Phase 3 study published in August 2026.
The pill combines two antiretroviral drugs, islatravir and lenacapavir, into a single weekly dose. Researchers found it matched the effectiveness of standard once-daily regimens in suppressing the virus to undetectable levels.
The finding is significant for people living with HIV who struggle with daily pill adherence. Missing doses can allow the virus to replicate and potentially develop resistance to medications. A weekly pill reduces the number of doses a patient must remember to take each week from seven to one.
The study was conducted across multiple countries and included participants with varying levels of prior treatment experience. Researchers reported that the weekly combination was well tolerated, with a side effect profile comparable to existing daily treatments.
Lenacapavir is already approved in some markets as an injectable treatment for HIV. Combining it with islatravir in an oral weekly formulation represents a different approach to delivering the drug.
The results were reported by Healthline in early August 2026. Regulatory submissions for the weekly pill have not yet been announced, and the timeline for potential approval in the United States or other markets was not specified in the published findings.
